Carrum Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 35)
Carrum Health logo

Carrum Health

NicheHealthcare

Value-Based Surgical Care Platform

Carrum Health connects self-insured employers with Centers of Excellence (COE) hospital systems through bundled payment surgical care arrangements; raised $45M Series B in 2022;

AI VisibilityBeta
Overall Score
D35
Category Rank
#553 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
40
Gemini
33

About

Carrum Health is a San Francisco-based healthcare technology company founded in 2014 by Sach Jain. It operates a value-based care platform that connects self-insured employers directly with a curated national network of Centers of Excellence (COE) — high-quality regional hospital systems and surgical facilities — through bundled payment arrangements for elective and complex surgical procedures. Rather than routing employees through standard in-network insurance plans where surgical quality varies widely, Carrum's model steers patients to top-performing surgical centers, covers travel costs when necessary, and eliminates employee out-of-pocket costs entirely for covered procedures.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

35
Overall Score
90
#553
Category Rank
#2
77
AI Consensus
83
stable
Trend
stable
40
ChatGPT
92
40
Perplexity
93
33
Gemini
89
35
Claude
96
32
Grok
95

Key Details

Category
Value-Based Surgical Care Platform
Enterprise
Tier
Niche
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.